BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 17, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 8/14 cls
Amgen Inc. (NASDAQ:AMGN) Cowen Eric Schmidt Other Market outperform 1% $60.85
Lazard Joel Sendek Other Hold
UBS Maged Shenouda Price target Neutral
Schmidt lowered his FY10 revenue estimate to $15.2B from $15.3B after an FDA panel voted in favor of Prolia denosumab to treat bone loss in postmenopausal osteoporosis (PMO) and prostate cancer patients, but voted against approval to prevent bone loss in PMO, prostate and breast cancer and to treat breast cancer (see Cover Story).
Sendek lowered his sales estimates for Prolia on the FDA news. He now expects U.S. sales for FY11 to be $985M, down from $1.1B. Sendek also reduced his overall FY10 revenue and EPS estimates to $16.2B from $16.4B and to $5.20 from $5.25, respectively.
Shenouda lowered...

Read the full 975 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >